J. Hauert

发表

C1 Inhibitor Cross-linking by Tissue Transglutaminase*

P. Patston, M. Schapira, J. Hauert, 2000, The Journal of Biological Chemistry.

Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects.

J. Hauert, P. Wyld, M. Savcic, 1999, Seminars in thrombosis and hemostasis.

endothelium acute leukemia and inhibit blast cell adhesion to activated High levels of the shed form of L-selectin are present in patients with

P. Callegari, M. Schapira, J. Hauert, 2011 .

High levels of the shed form of L-selectin are present in patients with acute leukemia and inhibit blast cell adhesion to activated endothelium.

P. Callegari, M. Schapira, J. Hauert, 1994, Blood.

High levels of the shed form of L-selectin are present in patients with acute leukemia and inhibit blast cell adhesion to activated endothelium

P. Callegari, M. Schapira, J. Hauert, 1994 .

Necrosis of skin induced by coumarin in a patient deficient in protein S.

E. Kruithof, J. Hauert, F. Bachmann, 1989, BMJ.

Diurnal Variation of the Fibrinolytic System

E. Kruithof, J. Hauert, F. Bachmann, 1988, Thrombosis and Haemostasis.

Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase.

E. Kruithof, J. Tissot, P. Schneider, 1982, The Journal of clinical investigation.

Comparison of results of intravenous infusion of anistreplase versus streptokinase in acute myocardial infarction.

M. Schaller, J. Goy, U. Sigwart, 1993, The American journal of cardiology.

Formation and properties of C1‐inhibitor polymers

P. Patston, M. Schapira, J. Hauert, 1995, FEBS letters.

Fibrinolytic and Anticoagulant Activity After a Single Subcutaneous Administration of a Low Dose of Heparin or a Low Molecular Weight Heparin-Dihydroergotamine Combination

E. Kruithof, J. Hauert, F. Bachmann, 1988, Thrombosis and Haemostasis.

Diurnal Variation of the Fibrinolytic System

E. Kruithof, J. Hauert, F. Bachmann, 1988, Thrombosis and Haemostasis.

Fibrinogen Degradation Products Generation is the Major Determinant of Platelet Inhibition Induced by Plasminogen Activators in Platelet-rich Plasma

A. Iorio, Nenci Gg, P. Callegari, 1993 .

Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors.

E. Kruithof, C. Genton, J. Hauert, 1987, Blood.

Hypofibrinolysis in Patients with a History of Idiopathic Deep Vein Thrombosis and/or Pulmonary Embolism

E. Kruithof, J. Hauert, F. Bachmann, 1992, Thrombosis and Haemostasis.

Release of vascular plasminogen activator (v‐PA) after venous stasis: electrophoretic—zymographic analysis of free and complexed v‐PA

E. Kruithof, J. Hauert, F. Bachmann, 1985, British journal of haematology.

Monoclonal antibodies directed against human tissue-type plasminogen activator: a characterization of their species specificity, affinity and heavy-chain binding.

J. Cajot, E. Kruithof, W. Schleuning, 1987, Thrombosis research.

Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas

J. Tissot, J. Hauert, F. Bachmann, 1984, International journal of cancer.

Plasminogen activators in dextran sulfate-activated euglobulin fractions: a molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis.

W. Schleuning, M. Schapira, J. Hauert, 1989, Blood.

Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.

A. Iorio, G. Agnelli, P. Callegari, 1995, The Journal of laboratory and clinical medicine.

MODIFICATION OF HEMOSTATIC PARAMETERS DURING CARDIOPULMONARY BYPASS (CPB)EFFECTS OF HIGH DOSE APROTININ

J. Hauert, P. Chassot, J. Gardaz, 1991 .

Pelvic actinomycosis involving the lungs with ascites and pelvic lymphadenopathy

J. Hauert, P. Wyld, M. Savcic, 2008 .

The major lethal neurotoxin of the venom of Naja naja philippinensis. Purification, physical and chemical properties, partial amino acid sequence.

J. Hauert, J. Bargetzi, A. Sussmann, 2009, International journal of peptide and protein research.

A Template‐Assembled Synthetic Protein Surface Mimetic of the von Willebrand Factor A1 domain Inhibits Botrocetin‐Induced Platelet Aggregation

M. Mutter, G. Tuchscherer, O. Michielin, 2004, Chembiochem : a European journal of chemical biology.

[Acquired factor V inhibitor treated with intravenous immunoglobulins].

T. Buclin, J. Hauert, F. Bachmann, 1992, Schweizerische medizinische Wochenschrift.

Effects of hypoxia and acidosis on vascular plasminogen activator release in the pig ear perfusion system.

L. Tappy, J. Hauert, F. Bachmann, 1984, Thrombosis research.

Fibrinolysis in Normal Subjects - Comparison Between Plasminogen Activator Inhibitor and Other Components of the Fibrinolytic System

E. Kruithof, J. Hauert, G. Melle, 1988, Thrombosis and Haemostasis.

Reaction of Acetaldehyde with Human Platelets

J. Hauert, O. Spertini, F. Bachmann, 1992, Thrombosis and Haemostasis.

[Poor fibrinolytic response to venous occlusion: defect of endothelial cells or plasma interference?].

J. Hauert, F. Bachmann, M. Stalder, 1983, Schweizerische medizinische Wochenschrift.

Specific binding to isolated acetylcholine receptor of a synthetic peptide duplicating the sequence of the presumed active center of a lethal toxin from snake venom.

M. Juillerat, J. Hauert, J. Bargetzi, 1982, The Journal of biological chemistry.

[Hemophilia C, a deficiency of a contact phase protein which may involve a risk of hemorrhage].

J. Hauert, F. Bachmann, C. Francillon, 1992, Schweizerische medizinische Wochenschrift.

Surface grafting onto template-assembled synthetic protein scaffolds in molecular recognition.

G. Tuchscherer, T. Kovacsovics, J. Hauert, 2000, Biopolymers.

molecular analysis of factor XII- and prekallikrein- dependent fibrinolysis Plasminogen activators in dextran sulfate-activated euglobulin fractions: a

M. Schapira, J. Hauert, F. Bachmann, 2011 .

Isolation fromHuman Plasmaofa Plasminogen Activator Identical toUrinary HighMolecular WeightUrokinase

J. Tissot, P. Schneider, J. Hauert, 1982 .